James N. Topper - May 9, 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
Director
Signature
/s/ Steve R. Bailey, Attorney-in-Fact For James N. Topper
Stock symbol
PHAT
Transactions as of
May 9, 2025
Transactions value $
$152,917
Form type
4
Date filed
5/13/2025, 04:13 PM
Previous filing
Mar 28, 2025
Next filing
May 15, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Topper James N Director 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO /s/ Steve R. Bailey, Attorney-in-Fact For James N. Topper 2025-05-13 0001341382

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Purchase $107K +33.4K $3.19 33.4K May 9, 2025 By Frazier Life Sciences X, L.P. F1, F2
transaction PHAT Common Stock Purchase $8.05K +2.23K +6.67% $3.62 35.6K May 9, 2025 By Frazier Life Sciences X, L.P. F2, F3
transaction PHAT Common Stock Purchase $38.3K +12.6K +35.39% $3.04 48.2K May 12, 2025 By Frazier Life Sciences X, L.P. F2, F4
holding PHAT Common Stock 5.83M May 9, 2025 By Frazier Life Sciences IX, L.P. F5
holding PHAT Common Stock 1 May 9, 2025 By FHMLS IX, L.L.C F6
holding PHAT Common Stock 32.1K May 9, 2025 Direct
holding PHAT Common Stock 3.91K May 9, 2025 By Topper Group III LLC F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $3.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2 The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.825 to $3.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4
F5 The shares reported herein are held of record by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F6 The shares reported herein are held of record by FHMLS IX, L.L.C. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F7 The Reporting Person is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.